Journal Watch · Nucleic Acids Research · 2026

VARIDT 4.0: distribution variability of drug transporters.

Overall, VARIDT 4.0 is expected to be a valuable data repository for system pharmacology, serving as an essential complement to existing pharmaceutical databases, and is freely accessible without login at https://idrblab.org/varidt/.

Li Y, Yang F, Pan Z et al.Nucleic Acids Research3 min readPharma relevance 65/100

DOI: 10.1093/nar/gkaf981PMID: 41036573Study type: clinical study

TL;DR

Overall, VARIDT 4.0 is expected to be a valuable data repository for system pharmacology, serving as an essential complement to existing pharmaceutical databases, and is freely accessible without login at https://idrblab.org/varidt/.

Key findings

  • Furthermore, by integrating these new distribution layers with its existing data, VARIDT 4.0 now enables comprehensive consideration of how a transporter's function is modulated by its specific spatiotemporal context.
  • Overall, VARIDT 4.0 is expected to be a valuable data repository for system pharmacology, serving as an essential complement to existing pharmaceutical databases, and is freely accessible without login at https://idrblab.org/varidt/.

What they did

Therefore, in this major update, VARIDT 4.0 was developed to provide a comprehensive resource, incorporating 25 797 tissue-level expression profiles, 451 830 cell-level expression records, and 1034 subcellular localization entries. Additionally, the foundational modules on general, structural, and regulatory variability were extensively updated. This multilevel variability data is highly relevant to the transport of 889 approved and 221 clinical trial drugs, as well as 689 endogenous metabolites, implicated in the treatment of 558 diseases.

Full abstract (original)

Background: The multilevel distribution variability of drug transporters-from tissues to cells and organelles-is critical for understanding drug response, drug-drug interactions, and multidrug resistance. The absorption, dispersion, metabolism, and excretion properties of drugs are codetermined by these multilevel distribution patterns, including tissue-specific expression, cellular heterogeneity, and subcellular localization. However, a public database that systematically integrates these crucial data of drug transporter distribution variability has been lacking.

What they did: Therefore, in this major update, VARIDT 4.0 was developed to provide a comprehensive resource, incorporating 25 797 tissue-level expression profiles, 451 830 cell-level expression records, and 1034 subcellular localization entries. Additionally, the foundational modules on general, structural, and regulatory variability were extensively updated. This multilevel variability data is highly relevant to the transport of 889 approved and 221 clinical trial drugs, as well as 689 endogenous metabolites, implicated in the treatment of 558 diseases.

Results & conclusions: Furthermore, by integrating these new distribution layers with its existing data, VARIDT 4.0 now enables comprehensive consideration of how a transporter's function is modulated by its specific spatiotemporal context. Overall, VARIDT 4.0 is expected to be a valuable data repository for system pharmacology, serving as an essential complement to existing pharmaceutical databases, and is freely accessible without login at https://idrblab.org/varidt/.

Abstract © the authors / Nucleic Acids Research (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1093/nar/gkaf981 · PubMed 41036573.

Why it matters for pharma & biotech

  • Relevant to Biology & Life Sciences teams tracking Nucleic Acids Research for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nucleic Acids Research study find?

Overall, VARIDT 4.0 is expected to be a valuable data repository for system pharmacology, serving as an essential complement to existing pharmaceutical databases, and is freely accessible without login at https://idrblab.org/varidt/.

What type of study is this?

It is a clinical study, published in Nucleic Acids Research in 2026. Therefore, in this major update, VARIDT 4.0 was developed to provide a comprehensive resource, incorporating 25 797 tissue-level expression profiles, 451 830 cell-level expression records, and 1034 subcellular localization entries.

Where can I read the original paper?

The original is at the publisher via DOI 10.1093/nar/gkaf981. PubMed ID: 41036573. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Li Y, Yang F, Pan Z et al.. VARIDT 4.0: distribution variability of drug transporters.. Nucleic Acids Research (2026). DOI: 10.1093/nar/gkaf981.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/varidt-4-0-distribution-variability-of-drug-transporters-kaf981/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides